SCHEMBL18222829

SCHEMBL18222829

CC(=O)OCC1CC2CC1C1CCCC21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 2/20 0.40
MAPT P10636 3/20 0.36
ALDH1A1 P00352 3/20 0.36
CA12 O43570 2/20 0.36
GMNN O75496 2/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
LMNA P02545 2/20 0.36
BLM P54132 2/20 0.36
CA9 Q16790 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
SGMS1 Q86VZ5 1/20 0.36
SGMS2 Q8NHU3 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
KDM4E B2RXH2 1/20 0.35
TP53 P04637 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
ALOX15 P16050 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2739902 0.88 CHRM1 (0.33) CHRM1MAPTALDH1A1CA12GMNN
SCHEMBL12641415 0.84 ALDH1A1 (0.44) CHRM1MAPTALDH1A1CA12GMNN
SCHEMBL18222843 0.84 CHRM1 (0.34) CHRM1MAPTALDH1A1CA12GMNN
SCHEMBL14491530 0.81 MAPT (0.34) MAPTALDH1A1CA12GMNNCA1
SCHEMBL23872913 0.80 HMGCR (0.34) MAPTALDH1A1CA12GMNNCA1
SCHEMBL16744315 0.80 CHRM1 (0.35) CHRM1MAPTALDH1A1CA12GMNN
SCHEMBL20962040 0.80 MAPT (0.32) MAPTALDH1A1CA12GMNNCA1
SCHEMBL18403070 0.80 CHRM1 (0.33) CHRM1
SCHEMBL21278894 0.80 TSHR (0.33) MAPTALDH1A1CA12GMNNCA1
SCHEMBL11982735 0.80 TSHR (0.33) MAPTALDH1A1CA12GMNNCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10928727-B2 Actinic ray-sensitive or radiation-sensitive resin composition, actinic ray-sensitive or radiation-sensitive film, mask blank including actinic ray-sensitive or radiation-sensitive film, pattern forming method, and method for manufacturing FUJIFILM CORPORATION (JP) 2021-02-23 US disclosed
EP-3098216-B1 NOVEL ESTER COMPOUND, AND COSMETIC COMPONENT AND COSMETIC PRODUCT EACH CONTAINING SAME KOKYU ALCOHOL KOGYO CO LTD (JP) 2019-11-06 EP disclosed
US-10010493-B2 Ester compound, and cosmetic component and cosmetic product each containing same KOKYU ALCOHOL KOGYO CO., LTD. (JP) 2018-07-03 US disclosed
US-20180120701-A1 ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE FILM, MASK BLANK INCLUDING ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE FILM, PATTERN FORMING METHOD, AND METHOD FOR MANUFACTURING ELECTRONIC DEVICE FUJIFILM CORPORATION (JP) 2018-05-03 US disclosed
EP-3098216-A1 NOVEL ESTER COMPOUND, AND COSMETIC COMPONENT AND COSMETIC PRODUCT EACH CONTAINING SAME Kokyu Alcohol Kogyo Co., Ltd. (JP) 2016-11-30 EP disclosed
US-20160331661-A1 NOVEL ESTER COMPOUND, AND COSMETIC COMPONENT AND COSMETIC PRODUCT EACH CONTAINING SAME KOKYU ALCOHOL KOGYO CO., LTD. (JP) 2016-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160331661-A1 NOVEL ESTER COMPOUND, AND COSMETIC COMPONENT AND COSMETIC PRODUCT EACH CONTAINING SAME DECR2, DECR1, CYP51A1 CHRM1 3199/4885MAPT 4201/4885ALDH1A1 235/4885
US-10010493-B2 Ester compound, and cosmetic component and cosmetic product each containing same DECR2, DECR1, CYP51A1 CHRM1 3111/4885MAPT 4054/4885ALDH1A1 273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.